All In Biotech

Drug Trial Radar · NCT06202261

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of TQB2930 for Injection Monotherapy or in Combination for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Recurrent / Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

154

Planned (sponsor's estimate)

Start

Apr 13, 2023

Primary completion

Dec 2026

Study completion Oct 2027

Sponsor

Sponsor type
Industry
First posted
Jan 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase Ib/II exploratory study. Phase Ib includes the dose escalation and expansion study of monotherapy, as well as the dose escalation study of combination therapy. After determining the maximum tolerated dose (MTD), a dose expansion study is conducted to observe the safety and efficacy in monotherapy. Phase II study is to further observe the safety and efficacy of TQB2930 combined with albumin-paclitaxel (cohort 3), or chemotherapy selected by investigators (cohort 4).

Conditions

  • Metastatic Breast Cancer
  • Recurrent Breast Cancer
  • Advanced Malignancies

Interventions

  • TQB2930 for injectionDrug

    TQB2930 for injection is a HER2 bispecific antibody.

  • Paclitaxel for injection (albumin-bound)Drug

    It is an anti-microtubule chemotherapy drug

  • TQB3616 capsuleDrug

    TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.

  • Fulvestrant injectionDrug

    Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol

  • Capecitabine tabletsDrug

    Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.

  • Vinorelbine tartrate injectionDrug

    Vinorelbine is an anti-tumor drug of vinca alkaloids.

  • Eribulin mesylate injectionDrug

    Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.

  • gemcitabine hydrochloride for injectionDrug

    Gemcitabine is a cell cycle specific anti-metabolic anticancer agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD)Time frame: Baseline up to 4 months
  2. Phase II recommended dose (P2RD)Time frame: Baseline up to 1 year
  3. Investigators assessed Objective remission rate (ORR) based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1Time frame: Baseline up to 2 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Cancer Hospital of Chongqing University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Affiliated cancer hospital of harbin medical university

    Harbin, Heilongjiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.